| Literature DB >> 25293512 |
Hai-Bo Chu1, Ting-Guo Zhang2, Jian-Hua Zhao3, Feng-Guo Jian4, Yong-Bo Xu5, Tao Wang6, Min Wang7, Jin-Yuan Tang8, Hong-Jie Sun9, Kun Li10, Wen-Jun Guo11, Xiao-Ji Zhu12.
Abstract
BACKGROUND: The spleen is thought to be central in regulating the immune system, a metabolic asset involved in endocrine function. Overwhelming postsplenectomy infection leads to a mortality rate of up to 50%. However, there is still controversy on performing subtotal splenectomy as treatment of splenomegaly due to portal hypertension in cirrhotic patients. In the present study, immunocytes and the indexes of splenic size, hemodynamics, hematology and immunology in the residual spleen were analyzed to support subtotal splenectomy due to splenomegaly.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25293512 PMCID: PMC4193139 DOI: 10.1186/s12865-014-0042-3
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Figure 1Immunohistochemical staining of T, B lymphocytes and macrophages (MØs) in residual spleen , splenomegaly and normal spleen. (A). Identification of T lymphocytes in PALS of residual spleen. (B). T lymphocytes in PALS of splenomegaly. (C). T lymphocytes in PALS of normal spleen (A-C, immunohistochemistry for CD45RO, ×400 magnification. Bars, 50 μm). (D). B lymphocytes in the splenic corpuscle and red pulp of residual spleen. (E). B lymphocytes in the splenic corpuscle and red pulp of splenomegaly. (F). B lymphocytes in the splenic corpuscle and red pulp of normal spleen (D-F, immunohistochemistry for CD20, ×400 magnification. Bars, 50 μm). (G). Identification of MØs in splenic cords and sinuses wall of residual spleen. (H). MØs in splenic corpuscle and MZ of residual spleen. (I). MØs in splenic cords and sinuses wall of splenomegaly. (J). MØs in splenic corpuscle and MZ of splenomegaly. (K). MØs in splenic cords and sinuses wall of normal spleen. (L). MØs in splenic corpuscle and MZ of normal spleen (G-L, immunohistochemistry for CD68, ×400 magnification. Bars, 50 μm).
Figure 2Images of clinical data. (A&B). CT images of preoperative and postoperative eight years. (C&D). Intraoperative splenomegaly and residual spleen. (E). Splenic scintigraphy with 99mTc sulfur colloid after eight years (residual, arrow).
Number of T and B Lymphocytes in Splenic Tissue (n = 13, means ± SD)
|
|
| |
|---|---|---|
|
|
| |
| Residual spleen | 59.77 ± 9.43a | 10.82 ± 1.94a |
| Splenomegaly | 34.72 ± 3.50b | 2.37 ± 0.66b |
| Control | 48.23 ± 14.87 | 6.84 ± 0.81 |
Compared with the splenomegaly and control group, a P < 0.05; compared with the control group, b P < 0.05.
Macrophage counts in splenic tissue (n = 13, means ± SD)
|
| ||
|---|---|---|
|
|
| |
| Residual spleen | 31.09 ± 9.73a | 16.69 ± 4.37 |
| Splenomegaly | 4.20 ± 0.88b | 15.77 ± 5.00 |
| Control | 7.46 ± 0.86 | 14.46 ± 2.90 |
Compared with the splenomegaly and control group, a P < 0.05; compared with the control group, b P < 0.05.
Comparison of splenic size, hemodynamic, hematological and immunological indices between the two groups (n = 13, means ± SD)
|
|
|
| |
|---|---|---|---|
| Splenic length (cm) | 47.77 ± 4.85 | 11.31 ± 1.11 | <0.01 |
| Splenic thickness (cm) | 10.00 ± 1.68 | 3.62 ± 0.51 | <0.01 |
| Splenic square area (cm2) | 387.20 ± 101.09 | 33.05 ± 7.31 | <0.01 |
| Splenic artery flow volume (ml/kg.min) | 7.51 ± 0.56 | 2.91 ± 0.03 | <0.01 |
| Portal venous diameter (cm) | 1.42 ± 0.04 | 1.15 ± 0.04 | <0.01 |
| Portal venous flow volume (ml/kg.min) | 19.72 ± 0.37 | 16.46 ± 0.37 | <0.01 |
| Leucocytes (×109/L) | 2320.77 ± 322.22 | 4261.54 ± 276.07 | <0.01 |
| Platelets (×109/L) | 51.30 ± 5.98 | 218.77 ± 28.69 | <0.01 |
| IgA (g/L) | 4.14 ± 0.34 | 4.34 ± 0.07 | >0.05 |
| IgM (g/L) | 3.04 ± 0.21 | 3.15 ± 0.10 | >0.05 |
| IgG (g/L) | 20.15 ± 1.32 | 21.21 ± 1.40 | >0.05 |
| Tuftsin (μg/L) | 603 ± 162 | 656 ± 147 | >0.05 |
Comparison of serum proportion of CD3 + T cells, CD4 + T cells, CD8 + T cells between the two groups (n = 13,%, means ± SD)
|
|
|
| |
|---|---|---|---|
| CD3+ T cells | 56.20 ± 2.90 | 65.68 ± 2.30 | <0.001 |
| CD4+ T cells | 32.90 ± 2.30 | 40.00 ± 2.90 | <0.001 |
| CD8+ T cells | 3.26 ± 0.20 | 24.60 ± 2.40 | <0.001 |
Comparison of serum levels of M-CSF and GM-CSF between the two groups (n = 13, ng/ml, means ± SD)
|
|
|
| |
|---|---|---|---|
| M-CSF | 3.19 ± 0.19 | 1.86 ± 0.18 | <0.001 |
| GM-CSF | 2.07 ± 0.18 | 0.39 ± 0.10 | <0.001 |
Comparison of the proportion of granulocyte, erythrocyte, megakaryocyte in bone marrow between the two groups (n = 13,%, means ± SD)
|
|
|
| |
|---|---|---|---|
| Myeloblast | 0.38 ± 0.04 | 0.35 ± 0.03 | >0.05 |
| Promyelocyte | 1.60 ± 0.12 | 1.70 ± 0.15 | >0.05 |
| Neutrophilic myelocyte | 6.62 ± 0.61 | 7.84 ± 0.59 | <0.001 |
| Neutrophilic metamyelocyte | 9.11 ± 0.81 | 12.81 ± 0.56 | <0.001 |
| Stabnuclear neutrophil | 15.52 ± 1.28 | 18.38 ± 0.48 | <0.001 |
| Neutrophilic granulocyte segmented form | 6.57 ± 1.18 | 16.17 ± 1.27 | <0.001 |
| Eosinophile granulocyte (per stage) | 6.06 ± 1.43 | 7.26 ± 1.86 | >0.05 |
| Basophilic leukocyte (per stage) | 0.04 ± 0.03 | 0.22 ± 0.18 | >0.05 |
| Macroblast of Naegeli | 0.67 ± 0.13 | 0.30 ± 0.07 | <0.001 |
| Basophilic erythroblast | 1.99 ± 0.17 | 0.79 ± 0.84 | <0.001 |
| Polychromatophilic erythroblast | 20.15 ± 1.37 | 5.81 ± 2.27 | <0.001 |
| Acidophilic normoblast | 13.11 ± 2.43 | 7.11 ± 1.93 | <0.001 |
| Megakaryoblast | 0.44 ± 0.17 | 0 | <0.001 |
| Immature megakaryoblast | 2.47 ± 1.83 | 0.20 ± 0.05 | <0.001 |
| Granula megakaryoblast | 61.56 ± 5.85 | 22.88 ± 1.59 | <0.001 |
| Maturity form megakaryoblast | 26.32 ± 2.56 | 71.13 ± 3.73 | <0.001 |
| Naked nucleus | 7.97 ± 5.32 | 4.66 ± 5.25 | >0.05 |